Panayiotis Hadjitheodorou, Wolfgang Roll, Emmanouil Alevroudis, Kyriaki Kyrou, Giorgos Adamou, Andreas Fesas, Mohammad Reza Pourkhessalian, Charalambia Kalogirou, Ioannis Tsechelidis, Alexis Vrachimis
{"title":"18F-FDG与18F-FAPI-74 PET在放射性碘难治性分化甲状腺癌患者中的头对头比较","authors":"Panayiotis Hadjitheodorou, Wolfgang Roll, Emmanouil Alevroudis, Kyriaki Kyrou, Giorgos Adamou, Andreas Fesas, Mohammad Reza Pourkhessalian, Charalambia Kalogirou, Ioannis Tsechelidis, Alexis Vrachimis","doi":"10.1967/s002449912780","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) was reported to outperform fluorine-18-fluorodeoxyglucose (<sup>18</sup>F-FDG) PET/CT in thyroid cancer in heterogenous patient collectives. This interim analysis of a prospective study aims to determine whether <sup>18</sup>F-FAPI-74 is superior to <sup>18</sup>F-FDG PET/CT in the distinct subgroup of radioactive-iodine (RAI)-refractory differentiated thyroid cancer (DTC).</p><p><strong>Subjects and methods: </strong>Ten patients with recurrent DTC, detected by elevated thyroglobulin, negative RAI-scan after thyroidectomy and RAI-therapy were prospectively included. All patients underwent <sup>18</sup>F-FAPI-74 and <sup>18</sup>F-FDG PET/CT. The diagnostic performances were compared on a per-patient and per-lesion basis.</p><p><strong>Results: </strong>Fluorine-18-FAPI-74 PET/CT missed tumour recurrence in one patient. Fluorine-18-FDG PET/CT revealed more metastases in three patients. No management change following <sup>18</sup>F-FAPI-74 PET/CT was documented. On a per-lesion analysis, the quantitative uptake values were significantly higher for <sup>18</sup>F-FDG than <sup>18</sup>F-FAPI-74 in all metastases (<sup>18</sup>F-FDG: median tumor to background ratio-TBRmax: 3.05 (1.02-9.55), <sup>18</sup>F-FAPI-74: median TBRmax: 1.09 (0.38-5.09); P<0.001) (<sup>18</sup>F-FDG: median TBRmean: 1.71 (0.65-11.53), <sup>18</sup>F-FAPI-74: median TBRmean: 0.64 (0.24-3.20). The detection rate was significantly higher for <sup>18</sup>F-FDG (29/71) compared to <sup>18</sup>F-FAPI-74 PET/CT (13/71, P<0.001).</p><p><strong>Conclusion: </strong>Fluorine-18-FDG-PET/CT outperforms <sup>18</sup>F-FAPI-74 PET/CT in RAI-refractory DTC in this prospective analysis.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"2-7"},"PeriodicalIF":0.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Head-to-head comparison of <sup>18</sup>F-FDG versus <sup>18</sup>F-FAPI-74 PET in radioactive-iodine refractory differentiated thyroid cancer patients.\",\"authors\":\"Panayiotis Hadjitheodorou, Wolfgang Roll, Emmanouil Alevroudis, Kyriaki Kyrou, Giorgos Adamou, Andreas Fesas, Mohammad Reza Pourkhessalian, Charalambia Kalogirou, Ioannis Tsechelidis, Alexis Vrachimis\",\"doi\":\"10.1967/s002449912780\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) was reported to outperform fluorine-18-fluorodeoxyglucose (<sup>18</sup>F-FDG) PET/CT in thyroid cancer in heterogenous patient collectives. This interim analysis of a prospective study aims to determine whether <sup>18</sup>F-FAPI-74 is superior to <sup>18</sup>F-FDG PET/CT in the distinct subgroup of radioactive-iodine (RAI)-refractory differentiated thyroid cancer (DTC).</p><p><strong>Subjects and methods: </strong>Ten patients with recurrent DTC, detected by elevated thyroglobulin, negative RAI-scan after thyroidectomy and RAI-therapy were prospectively included. All patients underwent <sup>18</sup>F-FAPI-74 and <sup>18</sup>F-FDG PET/CT. The diagnostic performances were compared on a per-patient and per-lesion basis.</p><p><strong>Results: </strong>Fluorine-18-FAPI-74 PET/CT missed tumour recurrence in one patient. Fluorine-18-FDG PET/CT revealed more metastases in three patients. No management change following <sup>18</sup>F-FAPI-74 PET/CT was documented. On a per-lesion analysis, the quantitative uptake values were significantly higher for <sup>18</sup>F-FDG than <sup>18</sup>F-FAPI-74 in all metastases (<sup>18</sup>F-FDG: median tumor to background ratio-TBRmax: 3.05 (1.02-9.55), <sup>18</sup>F-FAPI-74: median TBRmax: 1.09 (0.38-5.09); P<0.001) (<sup>18</sup>F-FDG: median TBRmean: 1.71 (0.65-11.53), <sup>18</sup>F-FAPI-74: median TBRmean: 0.64 (0.24-3.20). The detection rate was significantly higher for <sup>18</sup>F-FDG (29/71) compared to <sup>18</sup>F-FAPI-74 PET/CT (13/71, P<0.001).</p><p><strong>Conclusion: </strong>Fluorine-18-FDG-PET/CT outperforms <sup>18</sup>F-FAPI-74 PET/CT in RAI-refractory DTC in this prospective analysis.</p>\",\"PeriodicalId\":12871,\"journal\":{\"name\":\"Hellenic journal of nuclear medicine\",\"volume\":\" \",\"pages\":\"2-7\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hellenic journal of nuclear medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1967/s002449912780\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hellenic journal of nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1967/s002449912780","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/7 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Head-to-head comparison of 18F-FDG versus 18F-FAPI-74 PET in radioactive-iodine refractory differentiated thyroid cancer patients.
Objective: Fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) was reported to outperform fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT in thyroid cancer in heterogenous patient collectives. This interim analysis of a prospective study aims to determine whether 18F-FAPI-74 is superior to 18F-FDG PET/CT in the distinct subgroup of radioactive-iodine (RAI)-refractory differentiated thyroid cancer (DTC).
Subjects and methods: Ten patients with recurrent DTC, detected by elevated thyroglobulin, negative RAI-scan after thyroidectomy and RAI-therapy were prospectively included. All patients underwent 18F-FAPI-74 and 18F-FDG PET/CT. The diagnostic performances were compared on a per-patient and per-lesion basis.
Results: Fluorine-18-FAPI-74 PET/CT missed tumour recurrence in one patient. Fluorine-18-FDG PET/CT revealed more metastases in three patients. No management change following 18F-FAPI-74 PET/CT was documented. On a per-lesion analysis, the quantitative uptake values were significantly higher for 18F-FDG than 18F-FAPI-74 in all metastases (18F-FDG: median tumor to background ratio-TBRmax: 3.05 (1.02-9.55), 18F-FAPI-74: median TBRmax: 1.09 (0.38-5.09); P<0.001) (18F-FDG: median TBRmean: 1.71 (0.65-11.53), 18F-FAPI-74: median TBRmean: 0.64 (0.24-3.20). The detection rate was significantly higher for 18F-FDG (29/71) compared to 18F-FAPI-74 PET/CT (13/71, P<0.001).
Conclusion: Fluorine-18-FDG-PET/CT outperforms 18F-FAPI-74 PET/CT in RAI-refractory DTC in this prospective analysis.
期刊介绍：
The Hellenic Journal of Nuclear Medicine published by the Hellenic Society of
Nuclear Medicine in Thessaloniki, aims to contribute to research, to education and
cover the scientific and professional interests of physicians, in the field of nuclear
medicine and in medicine in general. The journal may publish papers of nuclear
medicine and also papers that refer to related subjects as dosimetry, computer science,
targeting of gene expression, radioimmunoassay, radiation protection, biology, cell
trafficking, related historical brief reviews and other related subjects. Original papers
are preferred. The journal may after special agreement publish supplements covering
important subjects, dully reviewed and subscripted separately.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
